Prognostic value of Minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 377-384

  Bader, Peter ^a   Kreyenberg, Hermann ^a   Henze, Günter H R ^a   Eckert, Cornelia ^a   Reising, Miriam ^a   Willasch, Andre ^a   Barth, Andrea ^a   Borkhardt, Arndt ^a   Peters, Christina ^a   Handgretinger, Rupert ^a   Sykora, Karl Walter ^a   Holter, Wolfgang ^a   Kabisch, Hartmut ^a   Klingebiel, Thomas ^a   Von Stackelberg, Arend ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE;

ADOLESCENT; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 58549091682     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.6065     Document Type: Article

References (44)

1. Einsiedel HG, von Stackelberg A, Hartmann R, et al: Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 23:7942-7950, 2005
2. von Stackelberg A, Hartmann R, Buhrer C, et al: High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood 1 1 1:2573-2580, 2008
3. Henze G, von Stackelberg A: Treatment of relapsed acute lymphoblastic leukemia, in Pui CH
4. (ed): Treatment of Acute Leukemias: New Directions for Clinical Research. Totowa, NJ, Humana Press, 2002, pp 199-219
5. Gaynon PS, Qu RP, Chappell RJ, et al: Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse - The Children's Cancer Group Experience. Cancer 82:1387-1395, 1998
6. Peters C, Schrauder A, Schrappe M, et al.: Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: The BFM/IBFM/EBMT concepts. Bone Marrow Transplant 35:S9-S11, 2005 (suppl 1)
7. Eckert C, Biondi A, Seeger K, et al: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358: 1239-1241, 2001
8. Borgmann A, von Stackelberg A, Hartmann R, et al: Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 101:3835-3839, 2003
9. Bader P, Beck J, Frey A, et al: Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 21:487-495, 1998
10. Bader P, Kreyenberg H, Hoelle W, et al: Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 22: 1696-1705, 2004
11. Chessells JM: Recent advances in management of acute leukaemia. Arch Dis Child 82:438-442, 2000
12. Knechtli CJ, Goulden NJ, Hancock JP, et al: Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 102:860-871, 1998
13. van der Velden VH, Joosten SA, Willemse MJ, et al: Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 15: 1485-1487, 2001
14. Bader P, Hancock J, Kreyenberg H, et al: Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16:1668-1672, 2002
15. Uzunel M, Mattsson J, Jaksch M, et al: The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 98:1982-1984, 2001
16. Sramkova L, Muzikova K, Fronkova E, et al: Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 48:93-100, 2007
17. Krejci O, van der Velden VH, Bader P, et al: Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: A report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 32:849-851, 2003
18. Sánchez J, Serrano J, Gomez P, et al: Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 116:686-694, 2002
19. Pongers-Willemse MJ, Seriu T, Stolz F, et al: Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 CONCERTED ACTION - Investigation of minimal residual disease in acuteleukemia. Leukemia 13:110-118, 1999
20. Szczepatński T, Orfao A, van der Velden VH, et al: Minimal residual disease in leukaemia patients. Lancet Oncol 2:409-417, 2001
21. Brüggemann M, Droese J, Bolz I, et al: Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 14:1419-1425, 2000
22. Verhagen OJ, Willemse MJ, Breunis WB, et al: Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14:1426-1435, 2000
23. van der Velden VH, Wijkhuijs JM, Jacobs DC, et al: T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 16:1372-1380, 2002
24. Kerst G, Kreyenberg H, Roth C, et al: Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 128: 774-782, 2005
25. van der Velden VH, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21: 604-611, 2007
26. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al: Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12:2006-2014, 1998
27. Eckert C, Landt O: Real-time PCR to detect minimal residual disease in childhood ALL. Methods Mol Med 91:175-182, 2004
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, p 169
30. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
31. The R Foundation for Statistical Computing, Institut für Statistik und Wahrscheinlichkeitstheorie der Technischen Universität Wien: R, A Language and Environment for Statistical Computing and Graphics. Vienna, Austria, University of Vienna, 2003
32. Imashuku S, Terui K, Matsuyama T, et al: Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: Multi-institutional collaborative study in Japan. Bone Marrow Transplant 31:1 127-1 135, 2003
33. Goulden N, Bader P, van der Velden VH, et al: Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 122:24-29, 2003
34. Schilham MW, Balduzzi A, Bader P: Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Bone Marrow Transplant 35:S49-S52, 2005 (suppl 1)
35. Borgmann A, Zinn C, Hartmann R, et al: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer 44:257-268, 2008
36. Wassmann B, Pfeifer H, Goekbuget N, et al: Alternating versus concurrent schedules of ima-tinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108:1469-1477, 2006
37. Ottmann OG, Hoelzer D: The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia: Promises, pitfalls and possibilities. Hematol J 3:2-6, 2002
38. Lang P, Barbin K, Feuchtinger T, et al: Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood 103:3982-3985, 2004
39. Pui CH, Jeha S, Kirkpatrick P: Clofarabine. Nat Rev Drug Discov 4:369-370, 2005
40. Locatelli F, Bruno B, Zecca M, et al: Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: Results of a GITMO/EBMT randomized trial. Blood 96:1690-1697, 2000
41. Formánková R, Sedlacek P, Krskova L, et al: Chimerism-directed adoptive immunotherapy in prevention and treatment of post-transplant relapse of leukemia in childhood. Haematologica 88:117-118, 2003
42. Dominietto A, Lamparelli T, Raiola AM, et al: Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 100:3930-3934, 2002
43. Spinelli O, Peruta B, Tosi M, et al: Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 92:612-618, 2007
44. Bader P, Koscielnak E, Schlegel PG, et al: Combined chemo-immunotherapy in children with ALL who relapse after allogeneic stem cell transplantation: An option to induce long term remission. Bone Marrow Transplant 33:220, 2004